FiercePharma

RELVAR™ ELLIPTA™ gains approval in Japan for the treatment of asthma

GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved RELVAR™ ELLIPTA™ for the treatment ...
FiercePharma

GSK and Theravance announce positive data from two studies evaluating the efficacy and safety of Incruse™ Ellipta® when added to Relvar®/Breo® Ellipta® in patients with COPD

GSK and Theravance announce positive data from two studies evaluating the efficacy and safety of Incruse™ Ellipta® when added to Relvar®/Breo® Ellipta® in patients with COPD GlaxoSmithKline plc ...
Insider Monkey

Relvar Ellipta: GlaxoSmithKline and Theravance’s Drug for Respiratory Diseases

Relvar Ellipta: Over the past few days, research-based pharmaceutical GlaxoSmithKline plc (ADR) (NYSE:GSK) and biopharmaceutical company Theravance Inc (NASDAQ:THRX)’s Relvar Ellipta has been in the ...
PharmaTimes

GSK’s inhaler improves asthma control in ‘real world’ study

GlaxoSmithKline and Innoviva have unveiled data from a second ground-breaking Salford Lung Study (SLS) showing that Relvar Ellipta significantly improved asthma control versus patients’ standard ...
Medscape

CHMP Backs Relvar Ellipta for Asthma, COPD

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for fluticasone furoate/vilanterol (FF/VI) (Relvar Ellipta, ...
The Financial

Relvar Ellipta 100/25 mcg gains approval in Japan for use in patients with COPD

The FINANCIAL — GlaxoSmithKline plc on December 2 announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar Ellipta (fluticasone furoate / vilanterol 100/25 mcg) ...
FierceBiotech

GSK and Theravance Announce Regulatory Submissions for FF/VI in the US and Europe

Relvar(TM) and Breo(TM) Proposed as Brand Names for FF/VI in EU and US; New Dry Powder Inhaler Proposed to be Named Ellipta(TM) LONDON and SOUTH SAN FRANCISCO, Calif., Jul 13, 2012 -- GlaxoSmithKline ...
Daily Mail

New once-a-day inhaler that could ease the suffering of asthma patients is approved for use in Britain

The first once-a-day inhaler for asthma sufferers has been approved for use in Britain. The new treatment gives 24-hour help to asthmatics, many of whom are currently failing to keep the condition ...
PharmaTimes

GSK’s Relvar Ellipta shows benefit for COPD patients

Further results from the UK Salford Lung Study have been unveiled showing that GlaxoSmithKline's Relvar Ellipta is better than the standard of care in reducing exacerbations in patients with chronic ...
Pulse

Once-daily combination inhaler launched for asthma and COPD

A new once-daily inhaled corticosteroid and long-acting beta-2-agonist combination inhaler for treatment of both asthma and COPD is available on the NHS from this week. The new inhaler, from ...
London South East

Relvar Ellipta approved in Japan for COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar® Ellipta® (fluticasone furoate ...
Yahoo Finance

RELVAR(TM) ELLIPTA(TM) Gains Approval in Japan for the Treatment of Asthma

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Sep 20, 2013) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Japanese ...